PharmaFocus Today – Page 12 – media

A new option for breast cancer treatment! Daiichi Sankyo and AstraZeneca’s Dazhuoyou, jointly developed, has been approved in China for its first indication.

Daiichi Sankyo and AstraZeneca’s TROP2-targeting antibody-drug conjugate (ADC), Dazhuoyou (generic name: dedaburumab for injection), has been approved by the China National Medical Products Administration for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have previously received endocrine therapy and at least one line of chemotherapy in the advanced stage of the disease. Dazhuoyou is an Xd antibody-drug conjugate (ADC) targeting TROP2 developed using unique technology. It was developed by Daiichi Sankyo and co-developed with AstraZeneca. This is also the second DXd ADC designed using Daiichi Sankyo’s DXd ADC technology and approved in China. Breast cancer ranks second among malignant tumors in women in my country. In 2022, there were approximately 357,000 new cases of breast cancer in China, with approximately 75,000 deaths, posing a serious threat to women’s health. Approximately 70% of confirmed cases were HR-positive, ...
- Source: drugdu
- 82
- September 5, 2025
Innovative drug Torico for delaying the progression of type 1 diabetes approved in China

On September 3, Sanofiannounced that its Tilizumab Injection (trade name: Terico) has been approved by the China National Medical Products Administration (NMPA) for use in children aged 8 years and above and adults with stage 2 type 1 diabetes to delay progression to stage 3 type 1 diabetes. https://finance.eastmoney.com/a/202509033503446424.html
- Source: drugdu
- 84
- September 5, 2025
Argo Biopharma and Novartis Deepen Collaboration, Including Multiple Cardiovascular Products

On September 3, 2025, Argo Biopharma Co., Ltd. announced a new strategic collaboration agreement with Novartis (NYSE: NVS) to jointly develop multiple cardiovascular products. This new agreement expands upon the existing collaboration between the two parties. Under this agreement, Argo Biopharma granted Novartis an option for ex-China rights to two early-stage molecules for the treatment of severe hypertriglyceridemia (sHTG) and mixed dyslipidemia, as well as a right of first negotiation for BW-00112 (ANGPTL3). This product is currently in Phase II clinical trials in the United States and China, with Argo Biopharma leading the subsequent combination therapy clinical trials. For another preclinical siRNA drug candidate, Argo Biopharma granted Novartis an exclusive ex-China license, including a reciprocal option to share profits and losses (P&L) in the United States and China. This product is expected to initiate Phase I clinical trials in 2026. https://finance.eastmoney.com/a/202509053505318712.html
- Source: drugdu
- 82
- September 5, 2025
The anti-insomnia drug Dali Lesheng was launched on Ali Health

September 4th that Dalirexant (trade name: Covitra), a global next-generation insomnia drug introduced by Simcere Pharmaceuticals, officially launched on Alibaba Health . Currently, Dalirexant is the only DORA (dual orexin receptor antagonist)-class insomnia drug approved by the European Medicines Agency to improve daytime function. Originating in Switzerland, it was jointly developed and introduced by Simcere Pharmaceuticals and Idorsia. The drug has previously been approved for marketing in 11 countries, including the United States, the United Kingdom, Switzerland, Japan, Canada, and Hong Kong. (21st Century Business Herald) https://finance.eastmoney.com/a/202509043505017121.html
- Source: drugdu
- 86
- September 5, 2025
Signed a licensing agreement with Braveheart Bio for the HRS-1893 project

September 5, Hengrui Medicine announced in the morning that it had reached an agreement with BraveheartBio, Inc. (hereinafter referred to as “Braveheart Bio”) of the United States to have independent intellectual property rights .Category 1 innovative drugsHengrui is licensed the HRS-1893 (HRS-1893) program to Braveheart Bio for a fee. Braveheart Bio will pay Hengrui an upfront payment of US$65 million (consisting of US$32.5 million in cash and an equivalent of US$32.5 million in Braveheart Bio equity) and US$10 million in near-term milestone payments upon completion of technology transfer, for a total of US$75 million. Hengrui is eligible to receive milestone payments related to clinical development and sales, up to US$1.013 billion. https://finance.eastmoney.com/a/202509053505416531.html
- Source: drugdu
- 78
- September 5, 2025
The 2025 World Lung Cancer Conference is approaching, and the Hong Kong pharmaceutical ETF (159718. SZ) has risen by over 2%

On the afternoon of September 5th, Hong Kong stocks opened higher and continued to rise, with innovative drugs leading the way in gains. The Hong Kong pharmaceutical ETF (159718. SZ) now rose 2.14%, with a year-on-year increase of over 89%. Component stocks such as San Sheng Pharmaceutical (01530) rose 12.00%, Kangnuoyo-B (02162) rose 10.44%, Jingtai Holdings (02228) rose 7.25%, and stocks such as Huang Pharmaceutical (00013) and Tongyuan Kangzheng-B (02410) followed suit. On the news front, the 2025 World Congress on Lung Cancer (WCLC) will be held in Barcelona, Spain from September 6th to 9th. Several innovative drug leaders will release heavyweight new products during the conference. The release and exchange of research results at academic conferences will bring new development opportunities and market attention to innovative drug companies. Institutions are optimistic about the potential for valuation recovery in the innovative drug sector, and the logic is that in the ...
- Source: drugdu
- 81
- September 5, 2025
Continuous innovation in biopharmaceutical processes, leading the industry upgrade with ‘continuous flow production’

Over the past few decades, the biopharmaceutical industry has been constantly advancing. From initially relying on traditional mass production processes to now exploring more intelligent and efficient continuous flow processes, the entire industry is undergoing a profound transformation. This transformation is not only expected to improve the efficiency and quality of drug supply, but also directly related to the accessibility of patient medication and the sustainable development of the healthcare system. For the general public, these seemingly professional terms are actually closely related to our daily health. Recently, the life science group Sartorius teamed up with the Shanghai Biopharmaceutical Industry Association to hold the 2025 Enhanced Process Summit. The summit gathered industry experts, scholars, and business representatives from around the world, focusing on the cutting-edge trends and development paths of biopharmaceutical continuous flow strengthening processes, and re emphasizing the release of the “White Paper on Biopharmaceutical Continuous Flow Strengthening Processes”. ...
- Source: drugdu
- 63
- September 5, 2025
Daily probiotic reduces pouchitis risk after colon removal surgery but may not be cost-effective

A new UCLA Health study found that taking an 8-strain probiotic daily may reduce the risk of pouchitis, a common inflammatory condition that occurs after colon removal surgery for ulcerative colitis, but the treatment may not be worth the cost depending on a patient’s likelihood of flare-ups. The study, published in the journal Gastro Hep Advances, is the first to evaluate the cost-effectiveness of the probiotic treatment, which was shown in previous studies to be effective at preventing the initial onset of and the reoccurrence of pouchitis. The UCLA study affirmed that the probiotic formulation was effective at preventing pouchitis compared to patients taking no probiotics but found that the cost to third-party payers may outweigh those benefits in most cases unless the cost of the probiotic formulation is lowered. Our findings highlight that while probiotic treatments can reduce the risk of this complication, their high costs limit their overall ...
- Source: drugdu
- 72
- September 4, 2025
Wegovy Linked To Lower Heart Risks Than Similar Drugs, Study Shows

WEDNESDAY, Sept. 3, 2025 (HealthDay News) — The weight-loss drug Wegovy may lower the risk of heart attack, stroke or death more than similar medications, according to new research from its maker, Novo Nordisk. In a study of more than 21,000 patients with obesity and heart disease but no diabetes, those taking Wegovy — which contains the active ingredient semaglutide — saw a 57% greater reduction in heart-related risks compared to people taking tirzepatide, the ingredient in Eli Lilly’s weight-loss drugs Mounjaro and Zepbound. The findings were presented at a medical conference and have not yet been peer-reviewed or published. As such, they should be regarded as preliminary. “This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes,” Ludovic Helfgott, Novo Nordisk’s head of product and portfolio strategy, said in a news release. ...
- Source: drugdu
- 64
- September 4, 2025
OPM plans to acquire 100% of Pengli Biopharmaceuticals and lowers its private placement to 362 million yuan.

An announcement was issued on September 4, stating that the company plans to purchase 100% of the equity of Pengli Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Pengli Biotechnology” or “the target company”) through the issuance of shares and payment of cash, and to issue shares to no more than 35 specific investors to raise matching funds. The company previously received an audit inquiry letter from the Shanghai Stock Exchange and has completed its response to the relevant questions. The company’s independent financial advisor, accounting firm, law firm, and appraisal agency have reviewed the relevant matters in the audit inquiry letter and issued clear opinions. They have also revised the relevant documents and materials previously released by the company. The company has reviewed and self-examined the entire text of the “Restructuring Report” (revised draft), and has made minor additions to the text, which have no impact on the transaction ...
- Source: drugdu
- 75
- September 4, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.